5The National Institute of Neurological Disorders and StrokeRT-PA Stroke Study Group.Tissue plasminogen activatorfor acute ischemic stroke[J].N Engl J Med,1995,333(24):1581-1587.
6Sylaja PN, Demchuk AM. Intravenous thrombolytic therapy in acute ischemic stroke: the art and science of treatment decision making. Ann Indian Acad Neurol, 2008, 11 (5): 24-29.
7Lansberg MG, Thijs VN, Bammer R, et al; DEFUSE Investigators. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke, 2007, 38: 2275-2278.
8Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke, 2006, 37: 1332- 1333.
9Sylaja PN, Dong W, Grotta JC, et al. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care, 2007, 6:181-185.
10Sylaja PN, Cote R, Buchan AM, et al; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry, 2006, 77: 826-829.
